In adults with sickle cell disease hospitalized for acute chest syndrome (ACS) without pulmonary artery macrothrombosis, does therapeutic-dose anticoagulation with tinzaparin shorten ACS duration compared with prophylactic-dose anticoagulation?
Background: Hematologic emergencies in the critical care setting are rare but deadly complications that can often be managed appropriately if identified early on and received prompt intervention. In this 2-part review, we will discuss several hematologic emergencies and discuss the ...
Take Home Points 100k people in US have sickle cell, the majority will at some point develop acute chest syndrome (ACS) The mortality rate per episode is 3-9%, similar to those of STEMI ACS is a syndrome – CXR infiltrate ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
